MINT-CANDESARTAN TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
29-11-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CANDESARTAN CILEXETIL
Fáanlegur frá:
MINT PHARMACEUTICALS INC
ATC númer:
C09CA06
INN (Alþjóðlegt nafn):
CANDESARTAN
Skammtar:
16MG
Lyfjaform:
TABLET
Samsetning:
CANDESARTAN CILEXETIL 16MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30/100/1000
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0135220003; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2018-06-05
Vara einkenni
MINT-CANDESARTAN Product Monograph
Page 1 of 34
PRODUCT MONOGRAPH
PR
MINT-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Mint Pharmaceuticals Inc., DATE OF REVISION:
6575 Davand Drive
November 29, 2022
Mississauga, Ontario
L5T 2M3
Submission
Control No: 265629
MINT-CANDESARTAN Product Monograph
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
....................................................................................................
8
DRUG
INTERACTIONS....................................................................................................13
DOSAGE AND
ADMINISTRATION.................................................................................14
OVERDOSAGE
.................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
................................................................17
STORAGE AND
STABILITY............................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................20
PART II: SCIENTIFIC
INFORMATION................................................................................21
PHARMACEUTICAL
INFORMATION.............................................................................21
CLINICAL TRIALS
..........................................................................................
Lestu allt skjalið
